{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:05:19Z","timestamp":1784617519970,"version":"3.55.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.TBZMED.VCR.REC.1403.029"],"award-info":[{"award-number":["IR.TBZMED.VCR.REC.1403.029"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cyto.2026.157177","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:18:18Z","timestamp":1781209098000},"page":"157177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy"],"prefix":"10.1016","volume":"205","author":[{"given":"Sevda","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Zarredar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ostadrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailar","family":"Nakhlband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Montazersaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naimeh Mesri","family":"Alamdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2026.157177_bb0005","series-title":"Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy","first-page":"201","article-title":"Functions of immune checkpoint molecules beyond immune evasion","author":"Zhang","year":"2020"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12935-023-03058-7","article-title":"Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds","volume":"23","author":"Amiri","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern. Med."},{"issue":"17","key":"10.1016\/j.cyto.2026.157177_bb0020","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2026.157177_bb0025","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1007\/s00018-020-03459-1","article-title":"Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer","volume":"77","author":"Jafari","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"13","key":"10.1016\/j.cyto.2026.157177_bb0030","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cyto.2026.157177_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0040","article-title":"Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ni.3432","article-title":"Parallels and differences between innate and adaptive lymphocytes","volume":"17","author":"Bedoui","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0055","doi-asserted-by":"crossref","unstructured":"E.J. Peterson, J.S. Maltzman, T-cell activation and tolerance, Clinical Immunology, Elsevier, 2019, pp. 183\u2013196. (e1).","DOI":"10.1016\/B978-0-7020-6896-6.00012-0"},{"key":"10.1016\/j.cyto.2026.157177_bb0060","series-title":"Co-signal Molecules in T Cell Activation: Immune Regulation in Health and Disease","first-page":"3","article-title":"Co-signal molecules in T-cell activation: historical overview and perspective","author":"Azuma","year":"2019"},{"key":"10.1016\/j.cyto.2026.157177_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fimmu.2015.00421","article-title":"Novel immune check-point regulators in tolerance maintenance","volume":"6","author":"Guo","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0070","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3389\/fimmu.2020.589641","article-title":"Revisiting T cell tolerance as a checkpoint target for cancer immunotherapy","volume":"11","author":"N\u00fcssing","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.34172\/bi.2022.23698","article-title":"Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy","volume":"13","author":"Jafari","year":"2023","journal-title":"Bioimpacts"},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/cancers5020569","article-title":"Immunotherapy and immune evasion in prostate cancer","volume":"5","author":"Thakur","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.cyto.2026.157177_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112516","article-title":"The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer","volume":"146","author":"Alemohammad","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14216\/kjco.24322","article-title":"Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy","volume":"21","author":"Zaheer","year":"2025","journal-title":"Korean J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0095","first-page":"58","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000490025","article-title":"Evolving roles for targeting CTLA-4 in cancer immunotherapy","volume":"47","author":"Zhao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0105","first-page":"84","article-title":"Dysregulated expression of CD28 and CTLA-4 molecules in patients with acute myeloid leukemia and possible association with development of graft versus host disease after hematopoietic stem cell transplantation","volume":"10","author":"Ramzi","year":"2019","journal-title":"Int. J. Organ Transplant. Med."},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195958","article-title":"Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas","volume":"13","author":"Kassardjian","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0115","first-page":"5093","article-title":"Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer","volume":"15","author":"Lan","year":"2018","journal-title":"Oncol. Lett."},{"issue":"18","key":"10.1016\/j.cyto.2026.157177_bb0120","doi-asserted-by":"crossref","first-page":"26670","DOI":"10.18632\/oncotarget.8476","article-title":"Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cyto.2026.157177_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2026.157177_bb0130","series-title":"Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy","first-page":"33","article-title":"Roles of PD-1\/PD-L1 Pathway: Signaling, cancer, and beyond","author":"Ai","year":"2020"},{"issue":"1\u20133","key":"10.1016\/j.cyto.2026.157177_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"issue":"23","key":"10.1016\/j.cyto.2026.157177_bb0140","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/ijms20235821","article-title":"Beyond the cell surface: targeting intracellular negative regulators to enhance T cell anti-tumor activity","volume":"20","author":"Sitaram","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0145","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"52","key":"10.1016\/j.cyto.2026.157177_bb0150","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.cyto.2026.157177_bb0155","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3390\/cancers11111756","article-title":"Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer","volume":"11","author":"Marhelava","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cyto.2026.157177_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2020","journal-title":"Gastroenterol. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cyto.2026.157177_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111186","article-title":"Novel immune checkpoint targets: a promising therapy for cancer treatments","volume":"126","author":"Patwekar","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.cyto.2026.157177_bb0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0200","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/intimm\/dxaa010","article-title":"PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-\u03b3 production, but lose cytotoxic activity in ovarian cancer","volume":"32","author":"Sawada","year":"2020","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00345-015-1656-7","article-title":"Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma","volume":"34","author":"Cai","year":"2016","journal-title":"World J. Urol."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0195","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.imbio.2012.01.012","article-title":"Down-regulation of interleukin-2 production by CD4+ T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription","volume":"217","author":"Lee","year":"2012","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","article-title":"Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma","volume":"29","author":"Xu","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2026.157177_bb0220","article-title":"A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors","volume":"5","author":"Weiss","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08054-6","article-title":"TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer","volume":"21","author":"Cabioglu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cyto.2026.157177_bb0225","series-title":"Phase 1 Trial of TIM-3 Inhibitor Cobolimab Monotherapy and in Combination with PD-1 Inhibitors Nivolumab or Dostarlimab (AMBER)","author":"Falchook","year":"2022"},{"issue":"17","key":"10.1016\/j.cyto.2026.157177_bb0230","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-24-2131","article-title":"Correction: Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"30","author":"Curigliano","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0235","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0240","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3146","article-title":"Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: a phase I\/II trial in progress","volume":"38","author":"Desai","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2026.157177_bb0515","first-page":"115O21","article-title":"A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma","volume":"6","author":"Davar","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0520","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0525","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/j.jtho.2018.08.194","article-title":"MS28. 02 Combination IO+ IO","volume":"13","author":"Ahn","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0310","series-title":"Relatlimab (RELA) plus Nivolumab (NIVO) Versus NIVO in First-Line Advanced Melanoma: Primary Phase III Results from RELATIVITY-047 (CA224-047)","author":"Lipson","year":"2021"},{"key":"10.1016\/j.cyto.2026.157177_bb0530","doi-asserted-by":"crossref","first-page":"v611","DOI":"10.1093\/annonc\/mdx440.011","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.cyto.2026.157177_bb0535","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti\u2013programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0540","series-title":"NCT04552223: A Phase II Study of Nivolumab plus BMS-986016 (Relatlimab) in Patients with Metastatic Uveal Melanoma (UM)(CA224-094)","author":"Lutzky","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0545","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0295","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","article-title":"A phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance","volume":"29","author":"Yap","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-025-02990-x","article-title":"First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors","volume":"132","author":"Day","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.cyto.2026.157177_bb0355","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial","volume":"9","author":"Kim","year":"2023","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0550","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0380","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2021-152395","article-title":"TIG-007: study of EOS884448\/GSK4428859A alone, and in combination with iberdomide with or without dexamethasone, in participants with relapsed or refractory multiple myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2026.157177_bb0410","series-title":"Initial Results from a First-in-Human Phase 1 Study of SNS-101 (pH-Selective Anti-VISTA Antibody) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Tumors","author":"Sen","year":"2024"},{"key":"10.1016\/j.cyto.2026.157177_bb0425","first-page":"A238","article-title":"392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies","volume":"8","author":"Martinez","year":"2020","journal-title":"BMJ Special. J."},{"key":"10.1016\/j.cyto.2026.157177_bb0555","series-title":"Advanced Solid Tumors","article-title":"A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA","author":"Rodon Ahnert","year":"2023"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0440","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"A phase I, open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers","volume":"28","author":"Diab","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0475","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0450","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-20-1830","article-title":"OX40 agonist BMS-986178 alone or in combination with nivolumab and\/or ipilimumab in patients with advanced solid tumors","volume":"27","author":"Gutierrez","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0495","series-title":"A First-in-Human Phase I Study in Patients with Advanced and\/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015, a CTLA-4 x OX40 Bispecific Antibody","author":"Yachnin","year":"2020"},{"key":"10.1016\/j.cyto.2026.157177_bb0560","series-title":"A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors, ClinicalTrials. gov: NCT02318394, First Posted: Dec 17","author":"MedImmune","year":"2014"},{"issue":"16","key":"10.1016\/j.cyto.2026.157177_bb0565","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","article-title":"First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0570","series-title":"A Phase Ib Dose Escalation Study of the OX40 Agonist MOXR0916 and the PD-L1 Inhibitor Atezolizumab in Patients with Advanced Solid Tumors","author":"Infante","year":"2016"},{"key":"10.1016\/j.cyto.2026.157177_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.897991","article-title":"Utomilumab in patients with immune checkpoint inhibitor-refractory melanoma and non-small-cell lung cancer","volume":"13","author":"Hong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0490","series-title":"First-in-Human Phase I\/IIa Trial to Evaluate the Safety and Initial Clinical Activity of DuoBody\u00ae-PD-L1\u00d7 4\u20131BB (GEN1046) in Patients with Advanced Solid Tumors","author":"Jure-Kunkel","year":"2020"},{"issue":"3","key":"10.1016\/j.cyto.2026.157177_bb0505","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007364","article-title":"Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors","volume":"12","author":"Khushalani","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0580","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0250","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR\u2013CD3 complexes and suppresses signaling by driving co-receptor\u2013Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0265","series-title":"LAG3 Expression Profile and the Mechanisms Regulating LAG3 Expression and Function","author":"Graydon","year":"2021"},{"issue":"7","key":"10.1016\/j.cyto.2026.157177_bb0270","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.cyto.2026.157177_bb0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2021.09.009","article-title":"PD-1, CTLA-4, LAG-3, and TIGIT: the roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions","volume":"240","author":"Esen","year":"2021","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0280","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.cyto.2026.157177_bb0285","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1200\/JCO.23.02172","article-title":"Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma","volume":"42","author":"Hamid","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0305","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2018.09.003","article-title":"Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics","volume":"154","author":"Everett","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.cyto.2026.157177_bb0315","doi-asserted-by":"crossref","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0320","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0325","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2026.157177_bb0330","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"TIGIT, a novel immune checkpoint therapy for melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2026.157177_bb0335","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2019.04.008","article-title":"Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis","volume":"138","author":"Wei","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0340","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0345","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/cam4.2167","article-title":"Expression of immune checkpoint receptors indoleamine 2, 3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma","volume":"8","author":"St\u00e5lhammar","year":"2019","journal-title":"Cancer Med."},{"issue":"69","key":"10.1016\/j.cyto.2026.157177_bb0635","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S0959-8049(16)32890-8","article-title":"Pre-clinical efficacy in multiple syngeneic models with oral immune checkpoint antagonists targeting PD-L1 and TIM-3","volume":"1","author":"Sasikumar","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cyto.2026.157177_bb0665","series-title":"Aurigene Discovery Technologies Limited, Assignee, Immunosuppression Modulating Compounds","author":"Sasikumar","year":"2017"},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0610","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1021\/acs.joc.4c00430","article-title":"Process development of a macrocyclic peptide inhibitor of PD-L1","volume":"89","author":"Mukherjee","year":"2024","journal-title":"J. Org. Chem."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0645","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cyto.2026.157177_bb0670","first-page":"A255","article-title":"419 pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial","volume":"8","author":"Piha-Paul","year":"2020","journal-title":"BMJ Special J."},{"key":"10.1016\/j.cyto.2026.157177_bb0630","first-page":"P279","article-title":"An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer","volume":"5","author":"Lazorchak","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"40","key":"10.1016\/j.cyto.2026.157177_bb0600","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by ad-peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0675","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/2326-6066.CIR-17-0035","article-title":"Peptide blocking of PD-1\/PD-L1 interaction for cancer immunotherapy","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"21","key":"10.1016\/j.cyto.2026.157177_bb0680","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1111\/bph.12819","article-title":"Small-molecule modulators of the OX 40\u2013OX40 ligand co-stimulatory protein\u2013protein interaction","volume":"171","author":"Song","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cyto.2026.157177_bb0625","series-title":"Phase 1 Trial of CA-170, a Novel Oral Small Molecule Dual Inhibitor of Immune Checkpoints PD-1 and VISTA, in Patients (Pts) with Advanced Solid Tumor or Lymphomas","author":"Lee","year":"2017"},{"key":"10.1016\/j.cyto.2026.157177_bb0685","series-title":"AACR Annual Meeting","article-title":"AUPM-170: first-in-class, oral immune checkpoint inhibitor of PD-L1\/2 and VISTA","author":"Sasikumar","year":"2015"},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0690","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.18632\/oncotarget.24283","article-title":"Analysis of response rate with ANTI PD1\/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials","volume":"9","author":"Carretero-Gonz\u00e1lez","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0695","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0700","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2220\/biomedres.40.243","article-title":"Antitumor activity of the PD-1\/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse","volume":"40","author":"Ashizawa","year":"2019","journal-title":"Biomed. Res."},{"issue":"3","key":"10.1016\/j.cyto.2026.157177_bb0705","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","article-title":"Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy","volume":"78","author":"Taylor","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0710","series-title":"Phase 1 study of INCB086550, an oral PD-l1 inhibitor, in Immune-Checkpoint Naive Patients with Advanced Solid Tumors","author":"Van Cutsem","year":"2021"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-00638-2","article-title":"Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT\/PVR","volume":"18","author":"Zhou","year":"2020","journal-title":"Cell Commun. Signal."},{"issue":"35","key":"10.1016\/j.cyto.2026.157177_bb0720","doi-asserted-by":"crossref","first-page":"15114","DOI":"10.1002\/anie.202002783","article-title":"A novel d-peptide identified by mirror-image phage display blocks TIGIT\/PVR for cancer immunotherapy","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0725","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/acschembio.9b00743","article-title":"An immune-stimulatory helix\u2013loop\u2013helix peptide: selective inhibition of CTLA-4\u2013B7 interaction","volume":"15","author":"Ramanayake Mudiyanselage","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.cyto.2026.157177_bb0730","series-title":"Vista antagonist and methods of use","author":"Noelle","year":"2016"},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0735","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.apsb.2020.01.005","article-title":"A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses","volume":"10","author":"Zhai","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"8004","key":"10.1016\/j.cyto.2026.157177_bb0350","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2026.157177_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103240","article-title":"Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)","volume":"64","author":"Zuo","year":"2021","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer\u2606","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2020.12.013","article-title":"A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity","volume":"534","author":"Han","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005829","article-title":"AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors","volume":"11","author":"Frentzas","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cyto.2026.157177_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/ITT.S260429","article-title":"VISTA: a promising target for cancer immunotherapy?","author":"Tagliamento","year":"2021","journal-title":"ImmunoTargets Ther."},{"issue":"6475","key":"10.1016\/j.cyto.2026.157177_bb0390","doi-asserted-by":"crossref","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cyto.2026.157177_bb0395","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","article-title":"Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma","volume":"57","author":"Kondo","year":"2016","journal-title":"Oral Oncol."},{"issue":"21","key":"10.1016\/j.cyto.2026.157177_bb0400","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cyto.2026.157177_bb0405","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0415","doi-asserted-by":"crossref","first-page":"1311658","DOI":"10.3389\/fimmu.2023.1311658","article-title":"A highly potent anti-VISTA antibody KVA12123-a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors","volume":"14","author":"Iadonato","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0420","series-title":"HMBD-002 Is a Novel, Neutralizing, Anti-VISTA Antibody Exhibiting Strong Preclinical Efficacy and Safety, Being Developed as a Monotherapy and in Combination with Pembrolizumab","author":"DiMascio","year":"2021"},{"key":"10.1016\/j.cyto.2026.157177_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000733","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.cyto.2026.157177_bb0435","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer","author":"Deng","year":"2019","journal-title":"Onco. Targets. Ther."},{"issue":"7","key":"10.1016\/j.cyto.2026.157177_bb0445","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543776.2019.1634690","article-title":"Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1","volume":"29","author":"Perez-Santos","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"10.1016\/j.cyto.2026.157177_bb0455","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/1873-3468.14079","article-title":"Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity","volume":"595","author":"Yang","year":"2021","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.cyto.2026.157177_bb0460","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-21-1382","article-title":"Neoadjuvant intratumoral immunotherapy with TLR9 activation and anti-OX40 antibody eradicates metastatic cancer","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.cyto.2026.157177_bb0465","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","article-title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","volume":"26","author":"Glisson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0470","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0480","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cyto.2026.157177_bb0485","series-title":"561 DuoBody\u00ae-PD-L1\u00d7 4\u20131BB (GEN1046) Induces Superior Immune-Cell Activation, Cytokine Production and Cytotoxicity by Combining PD-L1 Blockade with Conditional 4\u20131BB Co-Stimulation","author":"Muik","year":"2020"},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0500","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0510","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbrc.2021.04.078","article-title":"An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy","volume":"559","author":"Shi","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0585","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1800991","article-title":"The next generation of immunotherapy for cancer: small molecules could make big waves","volume":"202","author":"Kerr","year":"2019","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0590","first-page":"529","article-title":"Therapeutic targeting of immune checkpoints with small molecule inhibitors","volume":"11","author":"Smith","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.cyto.2026.157177_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.752065","article-title":"Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development","volume":"13","author":"Sasikumar","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0605","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/1535-7163.MCT-18-0737","article-title":"A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy","volume":"18","author":"Sasikumar","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0615","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40259-018-0303-4","article-title":"Small-molecule immune checkpoint inhibitors targeting PD-1\/PD-L1 and other emerging checkpoint pathways","volume":"32","author":"Sasikumar","year":"2018","journal-title":"BioDrugs"},{"issue":"15","key":"10.1016\/j.cyto.2026.157177_bb0620","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/molecules24152804","article-title":"CA-170\u2013a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0640","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/CAD.0000000000001685","article-title":"Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer","volume":"36","author":"Xiang","year":"2025","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0650","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","article-title":"Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells","volume":"15","author":"Shaw","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cyto.2026.157177_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650731","article-title":"Small molecule cyclotriazadisulfonamide abrogates the upregulation of the human receptors CD4 and 4-1BB and suppresses in vitro activation and proliferation of T lymphocytes","volume":"12","author":"Claeys","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/jpm14010068","article-title":"Inhibitors of immune checkpoints: small molecule-and peptide-based approaches","volume":"14","author":"Fuchs","year":"2024","journal-title":"J. Person. Med."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0740","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2009.04.031","article-title":"MicroRNAs: novel regulators in the hallmarks of human cancer","volume":"285","author":"Ruan","year":"2009","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.cyto.2026.157177_bb0745","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/ijms18122540","article-title":"The roles of microRNAs in regulating the expression of PD-1\/PD-L1 immune checkpoint","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0750","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.humimm.2014.01.006","article-title":"MiR-20b,-21, and-130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer","volume":"75","author":"Zhu","year":"2014","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.cyto.2026.157177_bb0755","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy\u2014blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.cyto.2026.157177_bb0760","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/febs.14030","article-title":"Noncoding RNA s and immune checkpoints\u2014clinical implications as cancer therapeutics","volume":"284","author":"Smolle","year":"2017","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0765","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/neuonc\/nov292","article-title":"MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints","volume":"18","author":"Wei","year":"2016","journal-title":"Neuro-oncology"},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0770","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0775","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.18632\/oncotarget.15213","article-title":"PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p","volume":"8","author":"Audrito","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.cyto.2026.157177_bb0780","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/s41388-019-0677-x","article-title":"Correction: control of PD-L1 expression by miR-140\/142\/340\/383 and oncogenic activation of the OCT4\u2013miR-18a pathway in cervical cancer","volume":"38","author":"Dong","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.cyto.2026.157177_bb0785","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10529-017-2397-z","article-title":"miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1","volume":"39","author":"Wang","year":"2017","journal-title":"Biotechnol. Lett."},{"issue":"3","key":"10.1016\/j.cyto.2026.157177_bb0790","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"issue":"13","key":"10.1016\/j.cyto.2026.157177_bb0795","doi-asserted-by":"crossref","first-page":"21609","DOI":"10.18632\/oncotarget.15450","article-title":"The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1","volume":"8","author":"Cioffi","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0800","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cbin.10826","article-title":"Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1","volume":"41","author":"Zhang","year":"2017","journal-title":"Cell Biol. Int."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0805","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000488634","article-title":"MiR-140 expression regulates cell proliferation and targets PD-L1 in NSCLC","volume":"46","author":"Xie","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0810","first-page":"272","article-title":"miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway","volume":"40","author":"Wan","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0815","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/0008-5472.CAN-18-1397","article-title":"miR-146a controls immune response in the melanoma microenvironment","volume":"79","author":"Mastroianni","year":"2019","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cyto.2026.157177_bb0820","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-18-0831","article-title":"miRNA-148a-3p regulates immunosuppression in DNA mismatch repair\u2013deficient colorectal cancer by targeting PD-L1","volume":"17","author":"Ashizawa","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.cyto.2026.157177_bb0825","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2015.10","article-title":"The clinical relevance of the miR-197\/CKS1B\/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer","volume":"23","author":"Fujita","year":"2015","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.cyto.2026.157177_bb0830","first-page":"1461","article-title":"miR-375 inhibits IFN-\u03b3-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2\/STAT1 signaling","volume":"39","author":"Wu","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0835","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0840","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41467-018-03584-3","article-title":"Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion","volume":"9","author":"Sun","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2026.157177_bb0845","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0850","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1038\/ncomms11406","article-title":"miR-424 (322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint","volume":"7","author":"Xu","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0855","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1061186X.2018.1479755","article-title":"MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma","volume":"27","author":"Qu","year":"2019","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0860","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yexcr.2019.03.025","article-title":"miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint","volume":"380","author":"Li","year":"2019","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0865","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1111\/jcmm.13657","article-title":"The miR-3127-5p\/p-STAT 3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer","volume":"22","author":"Tang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cyto.2026.157177_bb0870","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","article-title":"MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells","volume":"41","author":"Gao","year":"2019","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0875","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14728222.2016.1162294","article-title":"MiRNA 34a: a therapeutic target for castration-resistant prostate cancer","volume":"20","author":"Chalanqui","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0880","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","article-title":"Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer","volume":"13","author":"Daige","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.cyto.2026.157177_bb0885","article-title":"PDCD1 (PD-1) is a direct target of miR-15a-5p and miR-16-5p","volume":"7","author":"Alexey","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0890","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1159\/000491909","article-title":"MiR-195\/\u221216 family enhances radiotherapy via T cell activation in the tumor microenvironment by blocking the PD-L1 immune checkpoint","volume":"48","author":"Tao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.cyto.2026.157177_bb0895","first-page":"1427","article-title":"MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1","volume":"19","author":"Nong","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cyto.2026.157177_bb0900","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-020-02507-w","article-title":"miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0905","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.nano.2016.06.004","article-title":"Ligand-targeted bacterial minicells: futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells","volume":"12","author":"Jivrajani","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2026.157177_bb0910","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.21037\/tlcr.2017.12.01","article-title":"An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)","volume":"7","author":"Viteri","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.cyto.2026.157177_bb0915","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0920","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2026.157177_bb0925","series-title":"Nano-Enabled Medical Applications","first-page":"61","article-title":"Nanocarriers as an emerging platform for cancer therapy","author":"Peer","year":"2020"},{"issue":"5","key":"10.1016\/j.cyto.2026.157177_bb0930","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1039\/D3NR04777F","article-title":"AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors","volume":"16","author":"Carm\u00e8s","year":"2024","journal-title":"Nanoscale"},{"issue":"11","key":"10.1016\/j.cyto.2026.157177_bb0935","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202218128","article-title":"Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy","volume":"135","author":"Su","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.cyto.2026.157177_bb0940","doi-asserted-by":"crossref","first-page":"1487940","DOI":"10.3389\/fphar.2024.1487940","article-title":"Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157177_bb0945","doi-asserted-by":"crossref","first-page":"2413603","DOI":"10.1002\/adma.202413603","article-title":"Advanced polymeric nanoparticles for cancer immunotherapy: materials engineering, immunotherapeutic mechanism and clinical translation","volume":"37","author":"Jia","year":"2025","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.cyto.2026.157177_bb0950","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/biomedicines13092160","article-title":"STING-activating nanoparticles combined with PD-1\/PD-L1 blockade: a synergistic approach in cancer immunotherapy","volume":"13","author":"Bartusik-Aebisher","year":"2025","journal-title":"Biomedicines"},{"issue":"26","key":"10.1016\/j.cyto.2026.157177_bb0955","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1016\/j.febslet.2005.08.004","article-title":"The therapeutic potential of RNA interference","volume":"579","author":"Uprichard","year":"2005","journal-title":"FEBS Lett."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626000724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626000724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:57:10Z","timestamp":1784617030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466626000724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":191,"alternative-id":["S1043466626000724"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157177","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157177"}}